SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities and Exchange Act
January 31, 2006
----------------
Date of Report
(Date of earliest event reported)
GeNOsys, INC.
-------------
(Exact name of registrant as specified in its charter)
Utah 000-49817 87-0671592
---- --------- ----------
(State or other (Commission File Number) (IRS Employer
jurisdiction of Identification No.)
incorporation)
5063 North Riverpark Way
Provo, Utah 84604
-----------------
(Address of Principal Executive Offices)
(801) 420-9994
--------------
(Registrant's Telephone Number)
N/A
---
(Former Name or Former Address if changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant under any of
the following provisions (see general instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14-a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
------------------------
See the Press Release, Exhibit 99.1, attached hereto and incorporated
herein by reference.
Item 8.01 Other Events.
------------
On January 24, 2006, we executed a Research and Advisory Services
Agreement (the "Agreement") with IriSys Inc., a Pharmaceutical Formulation
Development and cGMP ("current good manufacturing practices") firm located in
San Diego, California.
Under the Agreement, IriSys will provide contract services to us to
support the development of a tablet that produces a known quantity of nitric
oxide when used in conjunction with development of our custom generators.
IriSys' development activities will include methods suitable for the
germination of the tablet properties and nitric oxide generation; the
formulated development of the components to determine the process of producing
tablets with acceptable characteristics for use in our generators; the
development of a blending and tableting process; prototype development;
packaging development; manufacturing and process development; stability
testing; and analytic methods validation.
These services are anticipated to commence on or about February
15, 2006, at an estimated cost of approximately $407,900, payable in various
increments based on progress billings over an estimated eight month period
during which IriSys estimates they will have completed these services.
Item 9.01 Financial Statements and Exhibits.
---------------------------------
Exhibit Number Description
- -------------- -----------
99.1 Press Release of January 31, 2006
Signatures
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the Registrant has duly caused this Current Report to be signed on its behalf
by the undersigned hereunto duly authorized.
GENOSYS, INC.
Dated: 1/31/06 /s/ John W.R. Miller
---------------- ----------------------------------
John W.R. Miller
President
GENOSYS INC. AWARDS CONTRACT TO IRISYS TO SUPPORT THE DEVELOPMENT OF PORTABLE
NITRIC OXIDEGENERATION
PROVO, Utah-- (BUSINESS WIRE)- Tuesday, January 31, 2006-GeNOsys (generated
nitric oxide systems) Inc, (OTC:BB GNYS), a medical research and development
company specializing in pharmaceutical, biotechnical and medical gas
generating systems, announces that the Company has signed an agreement with
IriSys, Inc. of San Diego, California to support the development of sufficient
quantity and purity of Nitric Oxide using GeNOsys' portable generating device.
The contractor will further develop processes for manufacturing stable product
and packaging methods using suitable components required for a FDA required
IND(investigational new drug) application.
Mr. Clark Mower, GeNOsys' Director stated, "We are happy to announce the
signing of a development contract with IriSys. We have been extremely
impressed with their scientific capability and responsiveness to the needs of
our Company. This contract represents a significant step toward our vision of
making cost effective portable Nitric Oxide production a reality. We look
forward to announcing additional strategic events in the near future."
GeNOsys USA Inc. (generated nitric oxide systems) is a medical research and
development company specializing in pharmaceutical, biotechnical and medical
gas generating systems. Nitric oxide gas will be one of the medical gases
that will be generated along with various combinations of beneficial medical
gases suitable for the control of human disease. GeNOsys management believes
it can reduce regulatory time by "proving equivalence" to existing, FDA
approved, nitric oxide, compressed gas cylinders. Distribution will be
accelerated through the use of already existing distribution networks that
currently sell related respiratory products. For further information, see the
Company's Website at: www.genosysusa.com
This press release may contain forward-looking statements including the
Company's beliefs about its business prospects and future results of
operations. These statements involve risks and uncertainties. Among the
important additional factors that could cause actual results to differ
materially from those forward-looking statements are risks associated with the
overall economic environment, changes in anticipated earnings of the company
and other factors detailed in the company's filings with the SEC. In addition,
the factors underlying Company forecasts are dynamic and subject to change and
therefore those forecasts speak only as of the date they are given. The
Company does not undertake to update them; however, it may choose from time to
time to update them and if it should do so, it will disseminate the updates to
the investing public.
Contact Information:
GeNOsys Inc., Provo
Michael Dancy, 801-746-3570
e-mail: investor@geNOsysusa.com
- - ### -